The iconic rise of Viagra has long been a benchmark of pharmaceutical success, however its legacy within the broader industry now raises questions about long-term gains. Alternative versions are eroding exclusivity , causing worries that betting on companies heavily reliant to Viagra's once-dominant position could be a dangerous strategy, especiall